EyePoint (EYPT) Income from Continuing Operations (2010 - 2026)
EyePoint (EYPT) reported Income from Continuing Operations of 120201000.0 for Q1 2026, down 129.33% on a YoY basis from 409884549.8 in Q1 2025, and down 77.79% sequentially from 67609000.0 in Q4 2025.
EyePoint (EYPT) Income from Continuing Operations (2010 - 2026) Analysis & Trends
EyePoint (EYPT) has 17 years of Income from Continuing Operations data on file, last reported at 120201000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 129.33% year-over-year to 120201000.0; the trailing twelve-month figure through Mar 2026 stood at 306968000.0 (down 99.33% YoY), and the FY2025 full-year result was 231962000.0, down 77.25% from the prior year.
- Income from Continuing Operations fell to 120201000.0 in Q1 2026, from 67609000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 16331000.0 in Q4 2023 to a low of 120201000.0 in Q1 2026.
- A 5-year average of 53164529.41 and a median of 44383000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations tumbled 643.39% in 2022 and jumped 72.55% in 2023, its largest moves.
- Tracing EYPT's Income from Continuing Operations over 5 years: stood at 44383000.0 in 2022, then surged by 63.2% to 16331000.0 in 2023, then plunged by 153.5% to 41399000.0 in 2024, then plunged by 63.31% to 67609000.0 in 2025, then tumbled by 77.79% to 120201000.0 in 2026.
- Business Quant data shows EYPT's Income from Continuing Operations at 120201000.0 in Q1 2026, 67609000.0 in Q4 2025, and 59732000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 | -120.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120.20 Mn |
| Dec 31, 2025 | -67.61 Mn |
| Sep 30, 2025 | -59.73 Mn |
| Jun 30, 2025 | -59.43 Mn |
| Mar 31, 2025 | -52.42 Mn |
| Dec 31, 2024 | -41.40 Mn |
| Sep 30, 2024 | -29.36 Mn |
| Jun 30, 2024 | -30.83 Mn |
| Mar 31, 2024 | -98.09 Mn |
| Dec 31, 2023 | -16.33 Mn |
| Sep 30, 2023 | -24.84 Mn |
| Jun 30, 2023 | -35.03 Mn |
| Mar 31, 2023 | -22.31 Mn |
| Dec 31, 2022 | -44.38 Mn |
| Sep 30, 2022 | -90.48 Mn |
| Jun 30, 2022 | -91.85 Mn |
| Mar 31, 2022 | -19.53 Mn |
| Dec 31, 2021 | -19.92 Mn |
| Sep 30, 2021 | -16.70 Mn |
| Jun 30, 2021 | -12.36 Mn |